Cells in the blood circulating through a vascular graft can contribute to endothelialization of its flow surface. We hypothesized that granulocyte colony-stimulating factor (G-CSF) could enhance this process by increasing circulating bone marrow progenitor cells. Ten dogs received composite grafts that were shielded from any source of endothelialization other than the circulating blood. On the seventh postoperative day and for 7 days thereafter, five dogs were injected subcutaneously with 10 mg/kg/day of human G-CSF. The additional five dogs, used as controls, received no G-CSF. Grafts were retrieved at 4 weeks. All dogs recovered promptly postoperatively. White cell counts in G-CSF dogs increased by an average of 9.5-fold at the end of treatment, and had returned to normal before retrieval. All grafts remained patent. G-CSF grafts had significantly higher endothelialization than the controls (82.2 +/- 9.2% vs. 23.7 +/- 4.4%, p = 0.0004), with extensive flow surface neointima, covered with a single layer of endothelium verified by FVIII/vWF and CD34 staining. Control grafts had virtually no neointima and were covered with a thin layer of fibrin coagulum. Significantly more endothelial-lined microvessels were also found in the G-CSF grafts than in the controls. Dogs treated with G-CSF have increased endothelialization of synthetic vascular grafts due to increased circulating bone marrow progenitor cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10016-001-0238-x | DOI Listing |
Respir Investig
January 2025
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation therapy, was recently approved for pharmaceutical use in Japan and shows promise as a treatment for autoimmune pulmonary alveolar proteinosis (APAP). For APAP patients with severe respiratory failure due to advanced lung fibrosis, lung transplantation is also a treatment option; however, APAP may recur after the procedure. Here, we report a case of successful sargramostim inhalation therapy for post-transplant APAP relapse in a patient who underwent living lung transplantation owing to severe fibrosis.
View Article and Find Full Text PDFClin Transl Sci
January 2025
Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea.
Granulocyte colony-stimulating factor (G-CSF) mobilizes peripheral blood (PB) progenitor cells from bone marrow (BM) into circulation for PB stem cell transplantation (PBSCT). This study aimed to develop a population pharmacokinetic-pharmacodynamic (PK-PD) model of filgrastim in healthy subjects to optimize PB CD34 cell collection. Plasma filgrastim concentrations and CD34 cell count data were obtained from a clinical study involving healthy Korean subjects.
View Article and Find Full Text PDFAnn Clin Transl Neurol
December 2024
Transplant and Cell Therapy Program, Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Objectives: Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment of MG is not broadly considered. Our objective is to report on the efficacy and safety of HSCT in refractory MG.
View Article and Find Full Text PDFWorld J Stem Cells
December 2024
Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Background: To date, no specific treatment has been established to reverse progressive chronic kidney disease (CKD).
Aim: To evaluate the safety and efficacy of autologous CD34 cell transplantation in CKD patients who exhibited a progressive decline in renal function.
Methods: The estimated glomerular filtration rate (eGFR) at the beginning of the study was 15.
Pediatr Blood Cancer
December 2024
Department of Hematology and Oncology, Beijing Jingdu Children's Hospital, Beijing, China.
Background: Primary hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome caused by immune dysregulation. Hematopoietic stem cell transplantation (HSCT) represents the only option for long-term cure for primary HLH. However, only around 25% of patients have a fully HLA-matched donor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!